Lawrence Erik Kurzius net worth and biography

Lawrence Kurzius Biography and Net Worth

Director of Elanco Animal Health

Lawrence E. Kurzius is the current Chairman of the Elanco Board of Directors and has served as a member of the Elanco Board of Directors since September 2018.

Lawrence Kurzius serves as Chairman and CEO of McCormick & Company. Throughout his tenure, he has served in several leadership positions, including Chief Operating Officer, Chief Administrative Officer, U.S. Consumer Foods President, and President of International Business.

Kurzius joined McCormick through the acquisition of Zatarain’s, where he was president and CEO. He also served as a Marketing Executive at Mars Inc. and the Quaker Oats Company.

Additionally, he serves on the boards of multiple not-for-profit industry groups including The Consumer Goods Forum, The Consumer Brands Association, and The National Association of Manufacturers. He is a member of Business Roundtable. Kurzius graduated magna cum laude from Princeton University.

What is Lawrence Erik Kurzius' net worth?: The estimated net worth of Lawrence Erik Kurzius is at least $2.09 million as of April 2nd, 2025. Kurzius owns 247,437 shares of Elanco Animal Health stock worth more than $2,089,358 as of April 18th. This net worth evaluation does not reflect any other assets that Kurzius may own. Learn More about Lawrence Erik Kurzius' net worth.
How do I contact Lawrence Erik Kurzius?: The corporate mailing address for Kurzius and other Elanco Animal Health executives is 2500 INNOVATION WAY, GREENFIELD IN, 46140. Elanco Animal Health can also be reached via phone at (877) 352-6261 and via email at kanaga_tiffany@elanco.com. Learn More on Lawrence Erik Kurzius' contact information.
Has Lawrence Erik Kurzius been buying or selling shares of Elanco Animal Health?: Lawrence Erik Kurzius has not been actively trading shares of Elanco Animal Health within the last three months. Most recently, on Tuesday, March 11th, Lawrence Erik Kurzius bought 10,000 shares of Elanco Animal Health stock. The stock was acquired at an average cost of $10.20 per share, with a total value of $102,000.00. Following the completion of the transaction, the director now directly owns 111,459 shares of the company's stock, valued at $1,136,881.80. Learn More on Lawrence Erik Kurzius' trading history.
Who are Elanco Animal Health's active insiders?: Elanco Animal Health's insider roster includes John Bilbrey (Director), Art Garcia (Director), Michael Harrington (Director), R. Hoover (Director), Lawrence Kurzius (Director), Rajeev Modi (Insider), Jeffrey Simmons (President & CEO), and Todd Young (Insider). Learn More on Elanco Animal Health's active insiders.
Are insiders buying or selling shares of Elanco Animal Health?: During the last year, Elanco Animal Health insiders bought shares 5 times. They purchased a total of 138,500 shares worth more than $1,818,675.00. The most recent insider tranaction occured on March, 11th when Director Lawrence Erik Kurzius bought 10,000 shares worth more than $102,000.00. Insiders at Elanco Animal Health own 0.6% of the company. Learn More about insider trades at Elanco Animal Health.
Information on this page was last updated on 3/11/2025.

Lawrence Erik Kurzius Insider Trading History at Elanco Animal Health

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/11/2025	Buy	10,000	$10.20	$102,000.00	111,459
3/7/2025	Buy	10,000	$10.90	$109,000.00	101,459
9/24/2018	Buy	10,000	$24.00	$240,000.00

Lawrence Erik Kurzius Buying and Selling Activity at Elanco Animal Health

Elanco Animal Health Company Overview

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Today's Range

Now: $8.44

$8.02

$8.46

50 Day Range

MA: $10.32

$8.14

$11.65

2 Week Range

Now: $8.44

$8.02

$18.80

Volume

5,406,589 shs

Average Volume

4,914,510 shs

Market Capitalization

$4.19 billion

P/E Ratio

21.11

Dividend Yield

N/A

Beta

1.44